Sublingual Buprenorphine/Naloxone Tied to More Adverse Dental Outcomes

FRIDAY, Dec. 16, 2022 (HealthDay News) -- There is a higher risk for adverse dental outcomes associated with sublingual buprenorphine/naloxone compared with transdermal buprenorphine or oral naltrexone, according to a research letter published in the Dec. 13 issue of the Journal of the American Medical Association.
Mahyar Etminan, Pharm.D., from the University of British Columbia in Vancouver, Canada, and colleagues used the PharMetrics database to examine the association between sublingual buprenorphine/naloxone and dental adverse events. The analysis included 21,404 new users of sublingual buprenorphine/naloxone, 5,385 users of transdermal buprenorphine, and 6,616 users of oral naltrexone.
The researchers found that the incidence of any dental adverse event was 21.6 per 1,000 person-years with sublingual buprenorphine/naloxone, 12.2 per 1,000 person-years with transdermal buprenorphine, and 10.9 per 1,000 person-years with oral naltrexone. The risk for dental adverse events was higher for sublingual buprenorphine/naloxone versus both transdermal buprenorphine (adjusted hazard ratio [aHR], 1.42) and oral naltrexone (aHR, 1.67). Similarly, the incidence of dental caries or tooth loss was 8.2 per 1,000 person-years with sublingual buprenorphine/naloxone, 3.5 per 1,000 person-years with transdermal buprenorphine, and 3.8 per 1,000 person-years with oral naltrexone. A higher risk for dental caries or tooth loss was seen for sublingual buprenorphine/naloxone versus both transdermal buprenorphine (aHR, 1.57) and oral naltrexone (aHR, 1.71).
"Clinicians might consider drugs other than sublingual buprenorphine/naloxone in patients with previous dental problems," the authors write. "These patients might also benefit from regular oral health examinations by their dentist."
Abstract/Full Text (subscription or payment may be required)
Related Posts
Un estudio confirma que los DIU son un método anticonceptivo muy efectivo
VIERNES, 25 de febrero de 2022 (HealthDay News) -- Usted acaba de tener su...
USPSTF: Evidence Lacking for Screening for Eating Disorders
TUESDAY, March 15, 2022 (HealthDay News) -- The U.S. Preventive Services Task...
MRI Best Supplemental Imaging Modality for Detecting Breast Cancer
MONDAY, Feb. 27, 2023 (HealthDay News) -- For non-high-risk women with dense...
Menopause Curriculum Lacking in Most Ob-Gyn Residency Programs
MONDAY, Aug. 14, 2023 (HealthDay News) -- Most obstetric and gynecology...